Lentiviral human AGFG2 sgRNA gene knockout kit

Lentiviral human AGFG2 sgRNA gene knockout kit

Catalog Number:
CGKK547032FEN
Mfr. No.:
HKO-610278
Price:
$878
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Kit Components: Lentiviral particles or plasmids for a set of three sgRNAs, and a pair of Indel screening PCR primers

          sgRNA lentiviral particle information
          • Functional titer: 1x10^8 TU/ml
          • Titration method: counting puromycin resistant cell clones
          • Purity: In vivo grade
          • Pseudotype: VSVG
          • Storage buffer: LentiShield™ lentivirus storage buffer
          • Storage: condition -80°C
          • Availability: 3-5 weeks

          sgRNA lentiviral plasmid information
          • Promoter for target sgRNA: U6
          • Mammalian selection: puromycin
          • Promoter for mammalian selection gene: EF1a
          • E.coli selection: Amp
          • Storage condition: -20°C
          • Availability: 1-2 weeks

          Please contact us at for specific academic pricing.

          Target Information

          Target Name
          Human AGFG2
          About Target
          Gene symbol: AGFG2
          Synonyms: HRBL RABR
          Species: HUMAN
          Gene ID: 3268
          Summary: This gene is a member of the HIV-1 Rev binding protein (HRB) family and encodes a protein with one Arf-GAP zinc finger domain, several phe-gly (FG) motifs, and four asn-pro-phe (NPF) motifs. This protein interacts with Eps15 homology (EH) domains and plays a role in the Rev export pathway, which mediates the nucleocytoplasmic transfer of proteins and RNAs. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. [provided by RefSeq, Feb 2013].
          NM numbers targeted (Accession number:Exon:CDS Fragment): NM_006076:4:4
      • Properties
        • * For Research Use Only.

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.